Purpose of the review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients. Recent findings: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies / Tini, Giacomo; Tocci, Giuliano; Battistoni, Allegra; Sarocchi, Matteo; Pietrantoni, Camilla; Russo, Domitilla; Musumeci, Beatrice; Savoia, Carmine; Volpe, Massimo; Spallarossa, Paolo. - In: CURRENT HEART FAILURE REPORTS. - ISSN 1546-9530. - 20:1(2023), pp. 1-7. [10.1007/s11897-023-00590-5]

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies

Tini, Giacomo
;
Tocci, Giuliano;Battistoni, Allegra;Pietrantoni, Camilla;Russo, Domitilla;Musumeci, Beatrice;Savoia, Carmine;Volpe, Massimo;
2023

Abstract

Purpose of the review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients. Recent findings: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.
2023
anthracycline; anti-vegf; arterial hypertension; arterial hypertension-mediated organ damage; cardio-oncology; cardiotoxicity
01 Pubblicazione su rivista::01a Articolo in rivista
Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies / Tini, Giacomo; Tocci, Giuliano; Battistoni, Allegra; Sarocchi, Matteo; Pietrantoni, Camilla; Russo, Domitilla; Musumeci, Beatrice; Savoia, Carmine; Volpe, Massimo; Spallarossa, Paolo. - In: CURRENT HEART FAILURE REPORTS. - ISSN 1546-9530. - 20:1(2023), pp. 1-7. [10.1007/s11897-023-00590-5]
File allegati a questo prodotto
File Dimensione Formato  
Tini_Role-of Arterial-Hypertension_2023 .pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 737.61 kB
Formato Adobe PDF
737.61 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1666793
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact